摘要
背景:尽管在肿瘤生物学研究领域取得了许多进展,但在大多数情况下,包括化疗在内的常规治疗仍然是首选。主要缺点这些治疗方法,除了许多抗肿瘤药物的低溶解度外,还缺乏特异性,导致因非特异性药物的吸收而产生严重的副作用。你的细胞。 目的:回顾和分析肿瘤纳米治疗的最新进展。 结果:纳米技术的进步及其在医学上的应用为纳米技术的发展提供了新的机遇和不同的智能系统。这些系统可以改善药物在细胞内的释放。他们的多功能和目标潜力。首先,我们提供了癌症和目前在肿瘤学中使用的各种智能纳米粒子的全球概况。然后,对开发人员进行了详细的分析。肿瘤治疗中的药物传递策略,主要集中在静脉注射智能纳米粒子。最后,我们讨论了挑战,临床试验,市场上的纳米医学和纳米治疗在癌症治疗中的应用前景。 结论:在这篇综述中,我们证明了智能给药系统在提高现有标准治疗方式(包括化疗)治疗效果方面的巨大潜力。治疗和放射治疗。
关键词: 纳米医学,纳米粒子,药物传递,癌症治疗,纳米技术,放射治疗。
图形摘要
Current Drug Targets
Title:Smart Drug-Delivery Systems for Cancer Nanotherapy
Volume: 19 Issue: 4
关键词: 纳米医学,纳米粒子,药物传递,癌症治疗,纳米技术,放射治疗。
摘要: Background: Despite all the advances achieved in the field of tumor-biology research, in most cases conventional therapies including chemotherapy are still the leading choices. The main disadvantage of these treatments, in addition to the low solubility of many antitumor drugs, is their lack of specificity, which leads to the occurrence of severe side effects due to nonspecific drug uptake by healthy cells.
Objective: The purpose of this manuscript is to review and analyze the recent progress made in cancer nanotherapy.
Results: Progress in nanotechnology and its application in medicine have provided new opportunities and different smart systems. Such systems can improve the intracellular delivery of the drugs due to their multifunctionality and targeting potential. First, we provide a global overview of cancer and different smart nanoparticles currently used in oncology. Then, we analyze in detail the development of drug-delivery strategies in cancer therapy, focusing mainly on the intravenously administered smart nanoparticles. Finally, we discuss the challenges, clinical trials, marketed nanomedicines and future directions of the nanotherapy applied to cancer treatment.
Conclusión: In this review, we have evidenced the tremendous potential that smart drug-delivery systems have to enhance the therapeutic effect of current standard treatment modalities, including chemotherapies and radiotherapies.
Export Options
About this article
Cite this article as:
Smart Drug-Delivery Systems for Cancer Nanotherapy, Current Drug Targets 2018; 19 (4) . https://dx.doi.org/10.2174/1389450117666160527142544
DOI https://dx.doi.org/10.2174/1389450117666160527142544 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Causes of Impaired Fertility in Women with Polycystic Ovary Syndrome
Current Women`s Health Reviews Corticosteroids for the Inflammatory Response to Cardiopulmonary Bypass: An Update
Current Pharmaceutical Design Synthesis and Biological Interest of Structured Docosahexaenoic Acid–Containing Triacylglycerols and Phospholipids
Current Organic Chemistry Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets Atrial Tachycardias Occurring Late After Open Heart Surgery
Current Cardiology Reviews Macrophages in Immunopathology of Atherosclerosis: A Target for Diagnostics and Therapy
Current Pharmaceutical Design Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Current Clinical Pharmacology Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design Azimilide, A Novel Oral Class III Antiarrhythmic for Both Supraventricular and Ventricular Arrhythmias
Current Drug Targets - Cardiovascular & Hematological Disorders Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology ACE Inhibitor Delapril Prevents Ca<sup>2+</sup>-Dependent Blunting of I<sub>K1</sub> and Ventricular Arrhythmia in Ischemic Heart Disease
Current Molecular Medicine Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System
Current Pharmaceutical Design Medical Devices for Telemedicine and Home Care Applications
Recent Patents on Biomedical Engineering (Discontinued) Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry